The results showed that higher serum IGF-I levels were associated with an increased risk of prostate cancer, with a combined odds ratio (OR) of 1.10 (95% CI: 1.02–1.18, P = 0.0136), which was statistically significant. Here, IGF1 is linked to prostate cancer.